Personalis (PSNL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +16.13%. A quarter ago, it was expected that this provider of contract research and genomic information would post a loss of $0.28 per share when it actually produced a loss of $0.24, delivering a surprise of +14.29%.Over the ...

Personalis (NasdaqGM:PSNL) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsAaron Tachibana - CFO and COOCaroline Corner - Investor Relations ContactChris Hall - CEO and PresidentJason Kritzer - Managing Director and Co-Head of Value TeamRich Chen - Chief Medical Officer and EVP of R&DTom Stevens - VPVidyun Bais - VP of Equity ResearchConference Call ParticipantsBill Bonello - Senior Research AnalystSubbu Nambi - Managing Director and Equity Research AnalystThomas Flaten - Senior Rese ...

Personalis (NasdaqGM:PSNL) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsAaron Tachibana - CFO and COOCaroline Corner - Investor Relations ContactChris Hall - CEO and PresidentJason Kritzer - Managing Director and Co-Head of Value TeamRich Chen - Chief Medical Officer and EVP of R&DTom Stevens - VPVidyun Bais - VP of Equity ResearchConference Call ParticipantsBill Bonello - Senior Research AnalystSubbu Nambi - Managing Director and Equity Research AnalystThomas Flaten - Senior Rese ...

Personalis (NasdaqGM:PSNL) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Speaker6Greetings, welcome to the Personalis fourth quarter 2025 earnings conference. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and then zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission File Number 001-38943 Personalis, Inc. (Exact name of Registrant as specified in its Charter) Delaware 27-5411038 (State or other jurisdiction ...

Core Insights - Personalis, Inc. has published a study demonstrating the effectiveness of its NeXT Personal® assay in monitoring immunotherapy responses in advanced cancers [1][2] Group 1: Study Findings - The study, led by UC San Diego Moores Cancer Center, highlights the ability of NeXT Personal to detect circulating tumor DNA (ctDNA) at ultrasensitive levels, allowing for earlier clinical interventions [3][4] - The interim analysis included 39 patients with advanced solid tumors across nine cancer types, treated with immune checkpoint inhibitors [4] - The NeXT Personal test tracks up to approximately 1,800 tumor-specific variants unique to each patient's tumor, enhancing its sensitivity [3] Group 2: Clinical Implications - Early identification of therapy response was observed, with molecular response detectable a median of 23 days after starting immunotherapy, leading to significantly longer progression-free survival for patients with early responses [7] - NeXT Personal identified molecular progression a median of 161 days before imaging in patients whose disease progressed, showcasing its potential as a predictive tool [7] - The study found that 33% of positive ctDNA detections occurred in the ultrasensitive range (below 100 PPM), which could be missed by less sensitive tests [7] Group 3: Overall Impact - Patients achieving molecular complete response (ctDNA clearance) had seven times higher overall survival compared to those who did not achieve clearance, indicating the assay's strong correlation with patient outcomes [7] - The findings reinforce the need for better tools to evaluate patient responses to immunotherapy, positioning NeXT Personal as a critical component in cancer treatment management [4]

Financial Performance - Personalis, Inc. announced preliminary financial results for Q4 and fiscal year 2025, with total revenue reaching $XX million, representing a YY% increase year-over-year[5] - The company reported a net loss of $ZZ million for the fiscal year 2025, compared to a net loss of $AA million in 2024, indicating a BB% improvement[5] - User data showed an increase in active customers to CC, up from DD in the previous year, reflecting a growth rate of EE%[5] - The company is projecting revenue for Q1 2026 to be between $FF million and $GG million, which would represent a growth of HH% compared to Q1 2025[5] Market Expansion - Personalis, Inc. is focusing on expanding its market presence in international regions, particularly in Europe and Asia, to drive future growth[5] - A strategic partnership was announced with a leading healthcare provider to integrate Personalis' solutions into their patient care protocols, expected to enhance user adoption[5] - The company is exploring potential acquisition opportunities to bolster its technology capabilities and market reach[5] Product Development and Innovation - The company is investing in new product development, particularly in genomic sequencing technologies, to enhance its service offerings[5] - The company emphasized its commitment to innovation and research, allocating JJ% of its revenue towards R&D initiatives in 2026[5] Operational Efficiency - Personalis, Inc. aims to improve operational efficiency, targeting a reduction in operating expenses by II% in the upcoming fiscal year[5]

Company Overview - Phreesia, Inc. (NYSE:PHR) is a healthcare technology company focused on enhancing patient intake and engagement while streamlining administrative processes in healthcare settings [1][5] - The company operates in a competitive landscape alongside peers such as Health Catalyst, Veracyte, Accolade, Castle Biosciences, and Personalis, each providing unique solutions in the healthcare technology sector [1] Financial Performance - Phreesia's Return on Invested Capital (ROIC) is -12.98%, indicating that the company is not generating returns above its cost of capital [2][5] - The company's Weighted Average Cost of Capital (WACC) is 6.71%, leading to a ROIC to WACC ratio of -1.93, which suggests inefficient capital utilization [2][5] Peer Comparison - Health Catalyst has a ROIC of -16.99% and a WACC of 6.12%, resulting in a ROIC to WACC ratio of -2.78, indicating even less efficient capital utilization than Phreesia [3] - Accolade and Personalis also exhibit negative ROIC to WACC ratios of -2.91 and -3.19, respectively, reflecting similar challenges in generating returns above their cost of capital [3] - Castle Biosciences has a ROIC of -4.44% and a WACC of 8.60%, resulting in a ROIC to WACC ratio of -0.52, which, while still negative, is closer to breaking even compared to other peers [4] Industry Challenges - Overall, Phreesia and its peers face significant challenges in generating sufficient returns to cover their cost of capital, which raises concerns for investors [4]

Core Insights - The article discusses the best genomics stocks to invest in, focusing on companies involved in genetic editing, testing, and sequencing [1] Regulatory Developments - The U.S. FDA has introduced a new regulatory pathway to expedite approvals for tailored gene-editing therapies, allowing combination clinical trials for individuals with related genetic conditions [2] - This new approach leverages advancements in CRISPR technology, enabling faster regulatory actions, particularly for rare disorders affecting small patient populations [3] Research Findings - A report from the American Journal of Human Genetics highlights the FDA's approval of platform studies that edit only the guide RNA for specific mutations, potentially lowering development costs and increasing access to treatments for disorders like phenylketonuria [4] Investment Methodology - The selection of the 12 best genomics stocks was based on hedge fund holdings and analysts' upside potential, with a focus on stocks that hedge funds favor [6][7] Company Highlights - **Personalis, Inc. (NASDAQ:PSNL)**: - Analysts have set a price target of $11, up from $9, citing upcoming catalysts in life science instruments and diagnostics [8] - The company has revised its 2025 sales forecast down to a range of $68 million to $73 million, with a projected net loss of about $85 million [9][10] - Personalis specializes in genomic sequencing and analytics for developing tailored cancer vaccines [11] - **Absci Corporation (NASDAQ:ABSI)**: - The company is conducting a Phase 1/2a clinical trial for ABS-201, an experimental anti-prolactin receptor antibody, with interim results expected in late 2026 [12] - H.C. Wainwright has increased its price target for Absci to $8, highlighting the potential of ABS-201 in enhancing hair follicle growth [13] - Absci focuses on using AI in synthetic biology to unlock the potential of proteins as next-generation drugs [14]

Core Insights - Personalis, Inc. has published a new study in Clinical Cancer Research, highlighting advancements in genomics for precision oncology [1] Company Summary - The study titled "Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy" was conducted by Dr. Rodrigo Toledo and a leading team at the Vall d'Hebron Institute of Oncology (VHIO) [1]